MX2017014390A - Piroglutamato de vortioxetina. - Google Patents
Piroglutamato de vortioxetina.Info
- Publication number
- MX2017014390A MX2017014390A MX2017014390A MX2017014390A MX2017014390A MX 2017014390 A MX2017014390 A MX 2017014390A MX 2017014390 A MX2017014390 A MX 2017014390A MX 2017014390 A MX2017014390 A MX 2017014390A MX 2017014390 A MX2017014390 A MX 2017014390A
- Authority
- MX
- Mexico
- Prior art keywords
- vortioxetine pyroglutamate
- pyroglutamate
- vortioxetine
- salt
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D207/28—2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención proporciona sal de piroglutamato de vortioxetina y composiciones farmacéuticas que comprenden la sal.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201500284 | 2015-05-13 | ||
| PCT/EP2016/060540 WO2016180870A1 (en) | 2015-05-13 | 2016-05-11 | Vortioxetine pyroglutamate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017014390A true MX2017014390A (es) | 2018-03-23 |
| MX375469B MX375469B (es) | 2025-03-06 |
Family
ID=55963369
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017014390A MX375469B (es) | 2015-05-13 | 2016-05-11 | Piroglutamato de vortioxetina. |
Country Status (44)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112018003930A2 (pt) | 2016-07-01 | 2018-09-25 | H Lundbeck As | regimes de dosagem de vortioxetina para início rápido de efeito antidepressivo |
| US10519121B2 (en) | 2016-12-30 | 2019-12-31 | Apicore Us Llc | Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts |
| EP3582759A4 (en) * | 2017-02-17 | 2021-01-06 | Unichem Laboratories Ltd | BIOEQUIVALENT PHARMACEUTICAL COMPOSITION OF VORTIOXETINE BROMHYDRATE |
| US11377416B2 (en) * | 2017-07-31 | 2022-07-05 | Small Pharma Ltd. | Crystalline forms of hydroxynorketamine |
| GB201715950D0 (en) * | 2017-10-02 | 2017-11-15 | Croda Int Plc | Gel composition comprising a phase change material |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| WO2021198778A1 (en) | 2020-04-03 | 2021-10-07 | H. Lundbeck A/S | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine for prevention or treatment of emotional blunting |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1006728A (en) * | 1962-12-31 | 1965-10-06 | Mundipharma Ag | Amine salts of pyrrolidone carboxylic acid |
| JPS6160620A (ja) | 1984-09-03 | 1986-03-28 | Teijin Ltd | ピログルタミン酸エステル類を含有する医薬品組成物 |
| US4780667A (en) | 1985-06-25 | 1988-10-25 | Hewlett-Packard Company | Magnetostatic wave delay line discriminator with automatic quadrature setting and automatic calibration |
| FR2694194B1 (fr) | 1992-07-31 | 1994-11-04 | Health Business Dev | Gel hydratant, médicament et composition cosmétique le contenant, procédé de préparation dudit gel. |
| ATE197900T1 (de) | 1996-08-15 | 2000-12-15 | Losan Pharma Gmbh | Gut schluckbare orale arzneiform |
| US6436946B1 (en) * | 1997-05-02 | 2002-08-20 | Morris A. Mann | Xanthine-containing compositions for oral administration and uses related thereto |
| SK284948B6 (sk) | 2000-04-06 | 2006-03-02 | Zentiva, A. S. | Liečivý prípravok s obsahom vápnika alebo zmesi vápnika a vitamínu D, alebo zmesi vápnika a horčíka v novej liekovej forme |
| UA81749C2 (uk) | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну |
| JP5154924B2 (ja) | 2004-05-11 | 2013-02-27 | エガレット エイ／エス | ジェランガムを含む膨張可能な投与形態 |
| EP2439201B1 (en) * | 2006-06-16 | 2013-08-07 | H. Lundbeck A/S | Compounds with combined sert, 5-ht3 and 5-ht1a activity |
| TW200932233A (en) * | 2007-11-13 | 2009-08-01 | Lundbeck & Co As H | Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity |
| HRP20140880T1 (hr) * | 2009-04-24 | 2014-11-07 | H. Lundbeck A/S | Tekuä†a formulacija soli 1-/2-(2,4 dimetilfenilsulfanil)fenil/piperazina |
| ME01602B (me) | 2009-08-24 | 2014-09-20 | H Lundbeck As | Nove kompozicije 1-[2 -(2,4-dimetil-fenilsulfanil)-fenil]piperazina |
| EP2564838A4 (en) | 2010-04-30 | 2014-06-04 | Takeda Pharmaceutical | ENTERICIAN TABLET |
| CN104797566B (zh) * | 2012-09-19 | 2017-07-07 | 桑多斯股份公司 | 沃替西汀氢溴酸盐的新结晶形式 |
| RS55932B1 (sr) | 2013-02-22 | 2017-09-29 | H Lundbeck As | Postupak za proizvodnju vortioksetina |
-
2016
- 2016-05-10 JO JOP/2016/0091A patent/JO3456B1/ar active
- 2016-05-11 HR HRP20190089TT patent/HRP20190089T1/hr unknown
- 2016-05-11 DK DK16721817.1T patent/DK3294719T3/en active
- 2016-05-11 SM SM20190053T patent/SMT201900053T1/it unknown
- 2016-05-11 TN TNP/2017/000453A patent/TN2017000453A1/en unknown
- 2016-05-11 WO PCT/EP2016/060540 patent/WO2016180870A1/en not_active Ceased
- 2016-05-11 AU AU2016259762A patent/AU2016259762B2/en active Active
- 2016-05-11 UA UAA201711057A patent/UA120779C2/uk unknown
- 2016-05-11 HK HK18111409.2A patent/HK1252099B/en unknown
- 2016-05-11 RU RU2017139002A patent/RU2713889C2/ru active
- 2016-05-11 MY MYPI2017001636A patent/MY184965A/en unknown
- 2016-05-11 PT PT16721817T patent/PT3294719T/pt unknown
- 2016-05-11 EP EP16721817.1A patent/EP3294719B1/en active Active
- 2016-05-11 SI SI201630176T patent/SI3294719T1/sl unknown
- 2016-05-11 PE PE2017002418A patent/PE20180039A1/es unknown
- 2016-05-11 CA CA2984615A patent/CA2984615C/en active Active
- 2016-05-11 GE GEAP201614622A patent/GEP20197020B/en unknown
- 2016-05-11 BR BR112017024039A patent/BR112017024039B8/pt active IP Right Grant
- 2016-05-11 ES ES16721817T patent/ES2709362T3/es active Active
- 2016-05-11 CN CN201680025327.1A patent/CN107567440B/zh active Active
- 2016-05-11 ME MEP-2019-11A patent/ME03312B/me unknown
- 2016-05-11 AR ARP160101356A patent/AR104591A1/es not_active Application Discontinuation
- 2016-05-11 JP JP2017558957A patent/JP6731001B2/ja active Active
- 2016-05-11 MX MX2017014390A patent/MX375469B/es active IP Right Grant
- 2016-05-11 CR CR20170506A patent/CR20170506A/es unknown
- 2016-05-11 HU HUE16721817A patent/HUE042893T2/hu unknown
- 2016-05-11 TR TR2019/01228T patent/TR201901228T4/tr unknown
- 2016-05-11 KR KR1020177032520A patent/KR102551429B1/ko active Active
- 2016-05-11 IL IL255466A patent/IL255466B/en unknown
- 2016-05-11 RS RS20190108A patent/RS58263B1/sr unknown
- 2016-05-11 MA MA043397A patent/MA43397A/fr unknown
- 2016-05-11 EA EA201792262A patent/EA032363B1/ru not_active IP Right Cessation
- 2016-05-11 LT LTEP16721817.1T patent/LT3294719T/lt unknown
- 2016-05-11 PL PL16721817T patent/PL3294719T3/pl unknown
- 2016-05-11 TW TW105114554A patent/TWI700276B/zh not_active IP Right Cessation
- 2016-05-12 US US15/152,902 patent/US10287261B2/en active Active
-
2017
- 2017-10-27 ZA ZA2017/07337A patent/ZA201707337B/en unknown
- 2017-11-02 CO CONC2017/0011295A patent/CO2017011295A2/es unknown
- 2017-11-03 DO DO2017000260A patent/DOP2017000260A/es unknown
- 2017-11-03 SV SV2017005560A patent/SV2017005560A/es unknown
- 2017-11-07 PH PH12017502028A patent/PH12017502028A1/en unknown
- 2017-11-09 CL CL2017002844A patent/CL2017002844A1/es unknown
- 2017-11-10 EC ECIEPI201774919A patent/ECSP17074919A/es unknown
-
2019
- 2019-01-24 CY CY20191100089T patent/CY1121171T1/el unknown
- 2019-03-06 US US16/294,647 patent/US11279682B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3015585C (en) | Pth prodrugs | |
| CL2016002772A1 (es) | Composiciones de insulina de rápida acción | |
| BR112018008901A8 (pt) | formulações subcutâneas de anticorpos anti-cd 38 e seus usos | |
| EP3305103A4 (en) | atomizing | |
| DOP2017000260A (es) | Piroglutamato de vortioxetina | |
| GEP20217239B (en) | Pharmaceutical composition | |
| EP3315035A4 (en) | atomizing | |
| HUE059623T2 (hu) | Páraképzõ rendszer | |
| DK3655038T3 (da) | Farmaceutisk sammensætning | |
| BR112016018062A8 (pt) | compostos terapêuticos, composição farmacêutica e usos | |
| FI3753929T3 (fi) | Dimeerisiä varjoaineita | |
| BR112016016274A2 (pt) | Ponte da barreira hematoencefálica | |
| EP3265098A4 (en) | COMPOSITIONS FOR MODULATING THE MECP2 EXPRESSION | |
| MX2018008302A (es) | Anticuerpo antigrupo de diferenciacion 9 (anti-cd9) terapeutico. | |
| GEP20217240B (en) | Pharmaceutical composition | |
| DK3582629T3 (da) | Marinade | |
| DK3583943T3 (da) | Farmaceutisk sammensætning | |
| IL265680B (en) | Dimeric contrast agents | |
| EP3682016A4 (en) | FORMULATIONS FOR THE ADMINISTRATION OF COMPOUNDS | |
| SMT202400478T1 (it) | Composizione farmaceutica | |
| ES1216222Y (es) | Composicion que comprende cenizas de cremacion | |
| EP3463589A4 (en) | PERFUME DISTRIBUTION SYSTEM | |
| EP3675918C0 (fr) | Systeme de diffusion de fragrances | |
| DK3096839T3 (da) | Duftende sammensætninger til kroppen | |
| ES2747993T8 (es) | Composiciones farmacéuticas de liberación prolongada de levetiracetam |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |